Maximizing the natriuretic peptide system in experimental heart failure: Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition

Horng Haur Chen, John G. Lainchbury, Gail J. Harty, John C Jr. Burnett

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background - A hallmark of congestive heart failure (CHF) is the elevation of the cardiac natriuretic peptides (NPs), which have natriuretic, renin-inhibiting, vasodilating, and lusitropic properties. We have reported that chronic subcutaneous (SQ) administration of brain natriuretic peptide (BNP) in experimental CHF improves cardiorenal function. Vasopeptidase inhibitors (VPIs) are single molecules that simultaneously inhibit both neutral endopeptidase 24.1 (NEP) and ACE. We hypothesized that acute VPI administration would potentiate the cardiorenal actions of SQ BNP in experimental CHF. Methods and Results-We determined the cardiorenal and humoral responses to acute VPI alone with omapatrilat (OMA) (1 μmol/kg bolus) (n = 6), acute low-dose SQ BNP (5 μg/kg) alone (n = 5), acute VPI plus low-dose SQ BNP (n = 5), and acute high-dose SQ BNP (25 μg/kg) alone in 4 groups of anesthetized dogs with experimental CHF produced by ventricular pacing for 10 days. Plasma BNP was greater with VPI+low -dose SQ BNP compared with VPI alone or low-dose SQ BNP alone and was similar to high-dose SQ BNP alone. Urinary BNP excretion was greatest with VPI+SQ BNP. Urinary sodium excretion was also highest with VPI+SQ BNP, with the greatest increase in glomerular filtration rate. VPI+SQ BNP resulted in a greater increase in cardiac output and reduction in cardiac filling pressures as compared with low-dose SQ BNP, high-dose SQ BNP, or VPI alone. Conclusions-This study reports that acute VPI potentiates the cardiorenal actions of SQ BNP in experimental CHF. This study advances the concept that protein therapy with BNP together with vasopeptide inhibition represents a novel therapeutic strategy in CHF to maximize the beneficial properties of the natriuretic peptide system.

Original languageEnglish (US)
Pages (from-to)999-1003
Number of pages5
JournalCirculation
Volume105
Issue number8
DOIs
StatePublished - Feb 26 2002

Fingerprint

Natriuretic Peptides
Brain Natriuretic Peptide
Heart Failure
Neprilysin

Keywords

  • Heart failure
  • Natriuretic peptides
  • Pacing

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Maximizing the natriuretic peptide system in experimental heart failure : Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition. / Chen, Horng Haur; Lainchbury, John G.; Harty, Gail J.; Burnett, John C Jr.

In: Circulation, Vol. 105, No. 8, 26.02.2002, p. 999-1003.

Research output: Contribution to journalArticle

@article{85b05cc6b3fb4c8e89dbcc6b4586d508,
title = "Maximizing the natriuretic peptide system in experimental heart failure: Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition",
abstract = "Background - A hallmark of congestive heart failure (CHF) is the elevation of the cardiac natriuretic peptides (NPs), which have natriuretic, renin-inhibiting, vasodilating, and lusitropic properties. We have reported that chronic subcutaneous (SQ) administration of brain natriuretic peptide (BNP) in experimental CHF improves cardiorenal function. Vasopeptidase inhibitors (VPIs) are single molecules that simultaneously inhibit both neutral endopeptidase 24.1 (NEP) and ACE. We hypothesized that acute VPI administration would potentiate the cardiorenal actions of SQ BNP in experimental CHF. Methods and Results-We determined the cardiorenal and humoral responses to acute VPI alone with omapatrilat (OMA) (1 μmol/kg bolus) (n = 6), acute low-dose SQ BNP (5 μg/kg) alone (n = 5), acute VPI plus low-dose SQ BNP (n = 5), and acute high-dose SQ BNP (25 μg/kg) alone in 4 groups of anesthetized dogs with experimental CHF produced by ventricular pacing for 10 days. Plasma BNP was greater with VPI+low -dose SQ BNP compared with VPI alone or low-dose SQ BNP alone and was similar to high-dose SQ BNP alone. Urinary BNP excretion was greatest with VPI+SQ BNP. Urinary sodium excretion was also highest with VPI+SQ BNP, with the greatest increase in glomerular filtration rate. VPI+SQ BNP resulted in a greater increase in cardiac output and reduction in cardiac filling pressures as compared with low-dose SQ BNP, high-dose SQ BNP, or VPI alone. Conclusions-This study reports that acute VPI potentiates the cardiorenal actions of SQ BNP in experimental CHF. This study advances the concept that protein therapy with BNP together with vasopeptide inhibition represents a novel therapeutic strategy in CHF to maximize the beneficial properties of the natriuretic peptide system.",
keywords = "Heart failure, Natriuretic peptides, Pacing",
author = "Chen, {Horng Haur} and Lainchbury, {John G.} and Harty, {Gail J.} and Burnett, {John C Jr.}",
year = "2002",
month = "2",
day = "26",
doi = "10.1161/hc0802.104282",
language = "English (US)",
volume = "105",
pages = "999--1003",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Maximizing the natriuretic peptide system in experimental heart failure

T2 - Subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition

AU - Chen, Horng Haur

AU - Lainchbury, John G.

AU - Harty, Gail J.

AU - Burnett, John C Jr.

PY - 2002/2/26

Y1 - 2002/2/26

N2 - Background - A hallmark of congestive heart failure (CHF) is the elevation of the cardiac natriuretic peptides (NPs), which have natriuretic, renin-inhibiting, vasodilating, and lusitropic properties. We have reported that chronic subcutaneous (SQ) administration of brain natriuretic peptide (BNP) in experimental CHF improves cardiorenal function. Vasopeptidase inhibitors (VPIs) are single molecules that simultaneously inhibit both neutral endopeptidase 24.1 (NEP) and ACE. We hypothesized that acute VPI administration would potentiate the cardiorenal actions of SQ BNP in experimental CHF. Methods and Results-We determined the cardiorenal and humoral responses to acute VPI alone with omapatrilat (OMA) (1 μmol/kg bolus) (n = 6), acute low-dose SQ BNP (5 μg/kg) alone (n = 5), acute VPI plus low-dose SQ BNP (n = 5), and acute high-dose SQ BNP (25 μg/kg) alone in 4 groups of anesthetized dogs with experimental CHF produced by ventricular pacing for 10 days. Plasma BNP was greater with VPI+low -dose SQ BNP compared with VPI alone or low-dose SQ BNP alone and was similar to high-dose SQ BNP alone. Urinary BNP excretion was greatest with VPI+SQ BNP. Urinary sodium excretion was also highest with VPI+SQ BNP, with the greatest increase in glomerular filtration rate. VPI+SQ BNP resulted in a greater increase in cardiac output and reduction in cardiac filling pressures as compared with low-dose SQ BNP, high-dose SQ BNP, or VPI alone. Conclusions-This study reports that acute VPI potentiates the cardiorenal actions of SQ BNP in experimental CHF. This study advances the concept that protein therapy with BNP together with vasopeptide inhibition represents a novel therapeutic strategy in CHF to maximize the beneficial properties of the natriuretic peptide system.

AB - Background - A hallmark of congestive heart failure (CHF) is the elevation of the cardiac natriuretic peptides (NPs), which have natriuretic, renin-inhibiting, vasodilating, and lusitropic properties. We have reported that chronic subcutaneous (SQ) administration of brain natriuretic peptide (BNP) in experimental CHF improves cardiorenal function. Vasopeptidase inhibitors (VPIs) are single molecules that simultaneously inhibit both neutral endopeptidase 24.1 (NEP) and ACE. We hypothesized that acute VPI administration would potentiate the cardiorenal actions of SQ BNP in experimental CHF. Methods and Results-We determined the cardiorenal and humoral responses to acute VPI alone with omapatrilat (OMA) (1 μmol/kg bolus) (n = 6), acute low-dose SQ BNP (5 μg/kg) alone (n = 5), acute VPI plus low-dose SQ BNP (n = 5), and acute high-dose SQ BNP (25 μg/kg) alone in 4 groups of anesthetized dogs with experimental CHF produced by ventricular pacing for 10 days. Plasma BNP was greater with VPI+low -dose SQ BNP compared with VPI alone or low-dose SQ BNP alone and was similar to high-dose SQ BNP alone. Urinary BNP excretion was greatest with VPI+SQ BNP. Urinary sodium excretion was also highest with VPI+SQ BNP, with the greatest increase in glomerular filtration rate. VPI+SQ BNP resulted in a greater increase in cardiac output and reduction in cardiac filling pressures as compared with low-dose SQ BNP, high-dose SQ BNP, or VPI alone. Conclusions-This study reports that acute VPI potentiates the cardiorenal actions of SQ BNP in experimental CHF. This study advances the concept that protein therapy with BNP together with vasopeptide inhibition represents a novel therapeutic strategy in CHF to maximize the beneficial properties of the natriuretic peptide system.

KW - Heart failure

KW - Natriuretic peptides

KW - Pacing

UR - http://www.scopus.com/inward/record.url?scp=0037176972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037176972&partnerID=8YFLogxK

U2 - 10.1161/hc0802.104282

DO - 10.1161/hc0802.104282

M3 - Article

C2 - 11864932

AN - SCOPUS:0037176972

VL - 105

SP - 999

EP - 1003

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 8

ER -